Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year, making cancer a new global pandemic with huge economic impact on the healthcare industry. Advances in molecular biology, cancer immunology and substantial knowledge on the differentiating traits between cancerous and normal cells have unlocked new opportunities to refine existing cancer therapies and develop novel ones that could more effectively address unmet medical needs. Treatment by triggering the body’s own immune system to fight diseases is an active area of research with the potential to transform cancer treatment using immunotherapy as a strategy. It is projected that the market for cancer immunotherapy could reach $35 billion a year in a decade.
ACI2014 looks at key market drivers and factors impacting growth on the adoption of immunotherapy strategies, and how its expanding use against cancer is delivering healthcare solutions that hold new therapeutic promises for cancer patients. Our stellar panel of speakers from the biomedical research, healthcare and biopharmaceutical sectors will discuss the latest and future developments in immunotherapy research; review the therapeutic potentials of cancer immunotherapies and targeted therapies; and examine the challenges as well as opportunities accompanying this new generation of innovative biopharmaceuticals fuelling growth in the oncology market.
Key Conference Topics
New approaches in cancer targeted therapies
Strategies to optimize immunotherapies
Innovative activation and suppression immunomodulators for diseases
Combination therapies and non-specific immunotherapies
Immunomodulatory agents for cancer treatment
Anti-cancer vaccines in preventive medicine
Autologous immune enhancement therapy
5 Reasons Why You Should Not Miss this Conference
Interact with our international panel of speakers for their insights on emerging and future industry trends with immunotherapies.
Network with decision-makers from leading and innovative companies for productive collaborations and business opportunities.
Connect with solution providers for innovative tools to accelerate and enable the success of preclinical research and development.
Explore with academia and researchers on novel research findings in cancer immunology that could be translated into clinical practice and anti-cancer drug development.
Invest your time with ASTRIK to understand the Now, know the Next and be empowered to take your business forward in the right direction.
Who Should Attend
Decision-makers from the Biopharmaceuticals, Pharmaceuticals, Healthcare, Biotechnology and Biomedical research sectors who are specialized in:
Tumor antigen discovery
Disease therapeutic target
+65 6853 9156